| 4.27 -0.06 (-1.39%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.76 | 1-year : | 6.73 |
| Resists | First : | 4.93 | Second : | 5.76 |
| Pivot price | 4.17  |
|||
| Supports | First : | 3.77 |
Second : | 3.05 |
| MAs | MA(5) : | 4.15  |
MA(20) : | 4 |
| MA(100) : | 3.17 |
MA(250) : | 3 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 49.4 |
D(3) : | 49.6 |
| RSI | RSI(14): 61.7 |
|||
| 52-week | High : | 13.93 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XBIO ] has closed below upper band by 40.6%. Bollinger Bands are 41.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 24 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.39 - 4.42 | 4.42 - 4.44 |
| Low: | 4.02 - 4.05 | 4.05 - 4.08 |
| Close: | 4.22 - 4.27 | 4.27 - 4.31 |
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Fri, 21 Aug 2026
Xenetic Biosciences, Inc. Revenue Breakdown – NASDAQ:XBIO - TradingView
Tue, 21 Jul 2026
XBIO Q2 2025 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - Dividend Increase Stocks - Vinanet
Tue, 26 May 2026
XBIO - Finviz
Sat, 13 Dec 2025
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - The State Journal-Register
Thu, 13 Nov 2025
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results - The Evening Sun
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 15.4 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 19 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.23 |
| Profit Margin | -76 % |
| Operating Margin | -147.1 % |
| Return on Assets (ttm) | -26.8 % |
| Return on Equity (ttm) | -47.1 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 1.39 |
| Sales Per Share | 1.39 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -3.72 |
| PEG Ratio | 0 |
| Price to Book value | 1.32 |
| Price to Sales | 3.06 |
| Price to Cash Flow | -4.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|